Bavarian Nordic gathers patients for PhIII RSV trial; Adaptimmune handed $37M+ as GSK partnership ends
Danish drugmaker Bavarian Nordic grabbed headlines last year for its production of a vaccine to treat the spread of mpox, and now it is turning …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
